Q2 FY2026 · ended Jun 30, 2026 · Revenue $961,138, -0.6% YoY · Filed Aug 12, 2026
Dyadic International Inc (DYAI) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $961,138 and a net loss of $2.1 million. As of Jun 30, 2026 it held $3.1 million in cash and investments and $5,054 in total debt.
Revenue
$961,138
-0.6% vs year-ago quarter
Net income
$-2.12M
-18.4% vs year-ago quarter
Operating cash flow
$-1.82M
-1298.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.06
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
36.44M
+0.7% vs year-ago quarter
Net cash
$3.11M
Q2 FY2026
Operating margin
-195.1%
TTM
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DYAI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Jupiter, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1213809
- Former names
- CCP WORLDWIDE INC (until Nov 5, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $961,138 | $1.1M | $565,526 | $1.2M | $966,630 |
| Operating income | -$2.1M | -$1.9M | -$1.5M | -$1.9M | -$1.7M |
| Net income | -$2.1M | -$2.0M | -$1.6M | -$2.0M | -$1.8M |
| Diluted EPS | -$0.06 | -$0.05 | -$0.06 | -$0.06 | -$0.06 |
| Operating cash flow | -$1.8M | -$2.0M | -$1.8M | -$1.9M | -$130,015 |
| Total assets | $6.5M | $7.8M | $9.9M | $11.7M | $8.1M |
| Total liabilities | $8.9M | $8.2M | $8.7M | $9.1M | $8.7M |
| Stockholders' equity | -$2.4M | -$407,732 | $1.2M | $2.6M | -$529,701 |
| Cash and investments | $3.1M | $5.6M | $7.3M | $8.9M | $5.0M |
| Total debt | $5,054 | $19,998 | $34,621 | $48,927 | $62,631 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Sep 25, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 14, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Other events
|
Jul 24, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
All 540 Dyadic International Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.